Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.65 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19597086 | 0.87 | ADORA2A (0.65) | ADORA2AADORA2BKMOGLSESR1 | |
| SCHEMBL17232702 | 0.87 | ADORA2A (0.62) | ADORA2AADORA2BKMOGLSESR1 | |
| SCHEMBL16682138 | 0.83 | HASPIN (0.50) | ADORA2AADORA2BKMOGLSESR1 | |
| SCHEMBL16682146 | 0.83 | KMO (0.46) | ADORA2AADORA2BKMOGLSESR1 | |
| SCHEMBL14928200 | 0.81 | ADORA2A (0.65) | ADORA2AADORA2BKMOGLSESR1 | |
| SCHEMBL16682190 | 0.80 | KMO (0.43) | ADORA2AADORA2BKMOGLSESR1 | |
| Ammonia Solution, Strong SCHEMBL905695 | 0.79 | ADORA2A (0.72) | ADORA2AADORA2BKMOGLSESR1 | |
| SCHEMBL13106177 | 0.78 | ADORA2A (0.59) | ADORA2AADORA2BKMOGLSESR1 | |
| Ammonia Solution, Strong SCHEMBL905842 | 0.77 | ADORA2A (0.59) | ADORA2AADORA2BKMOGLSESR1 | |
| SCHEMBL19006032 | 0.77 | ADORA2A (0.51) | ADORA2AADORA2BGLSKDM4CICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | ADORA2A 415/4885ADORA2B 611/4885KMO 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.